Phase 1 trail of simultaneously administered GM-CSF and IL-6 in patients with renal-cell carcinoma: Clinical and laboratory effects

Annals of Oncology

Volumn 12, Issue 5, 2001, Pages 655-659

  Tate, J ^a   Olencki, T ^a,b   Finke, J ^a,b   Kottke Marchant, K ^a   Rybicki, L A ^a   Bukowski, R M ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

GM CSF; Interleukin 6; Phase I trial

Indexed keywords

PADGEM PROTEIN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 6; ANTINEOPLASTIC AGENT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 6;

ADULT; AGED; ANEMIA; ANTIGEN EXPRESSION; ARTHRALGIA; ARTICLE; BURST FORMING UNIT E; CLINICAL ARTICLE; CLINICAL TRIAL; COLONY FORMING UNIT GEMM; COLONY FORMING UNIT GM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; KIDNEY CARCINOMA; LEUKOCYTOSIS; MALE; METASTASIS; MYALGIA; NAUSEA AND VOMITING; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTOSIS; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; KIDNEY TUMOR; MIDDLE AGED; PATHOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; HYPERBILIRUBINEMIA; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-6; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PLATELET ACTIVATION; THROMBOCYTOSIS; TREATMENT OUTCOME;

EID: 0034743787     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011123432765     Document Type: Article

References (27)

1. Cancer statistics
2. Renal cell carcinoma
3. Spontaneous regression of metastases of renal cancer: A report of two cases including the first recorded regression following irradiation of a dominant metastasis and review of the world literature
4. Treatment of renal cell carcinoma with escalating doses of alpha-interferon
5. Interferon alpha and survival in renal cell cancer
6. Recombinant beta-interferon in the treatment of patients with metastatic renal cell carcinoma
7. Complete response of metastatic renal cell carcinoma to low-dose interferon-γ treatment
8. Phase II trial of low dose γ-interferon in metastatic renal cell carcinoma
9. Phase II trial of high-dose intermittent interleukin-2 in metastatic renal cell carcinoma: A southwest oncology group study
10. Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: An outpatient multicenter trial
11. A phase II study of the continuous intravenous infusion of interleukin-6 for metastatic renal cell carcinoma
12. Recombinant human interleukin-6 in metastatic renal cell cancer: A phase II trial
13. Phase II trial of subcutaneously administered granulocyte-macrophage colony-stimulating factor in patients with metastatic renal cell carcinoma
14. The effect of antiplatelet drugs, heparin and preanalytical variables on platelet function detected by the platelet function analyzer (PFA-100TM)
15. Assessment of lumiaggregometry for research and clinical laboratories
16. In vitro efficacy of platelet glycoprotein IIb/IIIa antagonist in blocking platelet function in plasma of patients with heparin-induced thrombocytopenia
17. Two interferon mRNAs in human firbrolasts: In vitro translation and Escherichia coli cloning studies
18. 2-terminal amino acid sequence of a T-cell-derived lymphokine with growth factor activity for B-cell hybridomas
19. Regulation of interleukin-6 expression in cultured human blood monocytes and monocyte-derived macrophages
20. In vivo hematologic effects of recombinant interleukin-6 on hematopoiesis and circulating numbers of RBC's and WBC's
21. Interleukin 6: An overview
22. Antitumor activity of recombinant interleukin 6 in mice
23. Phase IA/IB trial of rhIL-6 in patients with refractory malignancy: Hematologic and immunologic effects
24. Production of interleukin-1α, interferon-1β and tumor necrosis factor by human mononuclear cells stimulated with granulocyte-macrophage colony-stimulating factor
25. Induction of cytokine messenger RNA and secretion in alveolar macrophages and blood monocytes from patients with lung cancer receiving granulocyte-macrophage colony-stimulating factor therapy
26. Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor
27. Induction of in vitro tumoricidal activity in alveolar macrophages and monocytes from patients with lung cancer